11.3 Pharmacoeconomics: ICER, QALY & Value Metrics

Pharmacoeconomics: ICER, QALY & Value Metrics

Executive Summary: Pharmacoeconomics identifies, measures, and compares the costs and consequences of pharmaceutical products and clinical pharmacy services. As ambulatory care pharmacists lead formulary management, value-based care initiatives, and comprehensive medication management programs, mastering the four core economic methodologies (CMA, CBA, CEA, CUA), computing Incremental Cost-Effectiveness Ratios (ICER), deriving Quality-Adjusted Life Years (QALY), navigating the cost-effectiveness plane, and applying analytical perspectives and discounting principles are vital competencies.

1. The Four Core Pharmacoeconomic Methodologies

Health economics applies economic principles to evaluate healthcare interventions. The four primary pharmacoeconomic methodologies are distinguished by how clinical consequences (outcomes) are measured and quantified:

1. Cost-Minimization Analysis (CMA)

• Prerequisite: Clinical efficacy and safety outcomes of the compared interventions MUST be proven completely equivalent prior to conducting the analysis (e.g., established via robust non-inferiority trials or bioequivalence studies).
• Cost Measurement: Monetary units (dollars, $).
• Outcome Measurement: Assumed identical / equivalent in all arms.
• Decision Rule: Select the lowest-cost alternative.
• Clinical Example: Comparing brand-name vs. AB-rated generic atorvastatin; comparing intravenous vs. oral bioequivalent fluoroquinolone step-down therapy; comparing two surgical anesthetic regimens with proven identical emergence times and adverse effect profiles.

2. Cost-Benefit Analysis (CBA)

• Cost Measurement: Monetary units (dollars, $).
• Outcome Measurement: Monetary units (dollars, $).
• Distinct Advantage: Because both inputs and consequences are valued in dollars, CBA can compare completely unrelated healthcare programs or allocate capital across disparate clinical service lines (e.g., comparing funding for a pharmacist-led ambulatory diabetes clinic vs. purchasing a new digital mammography unit vs. expanding an urgent care center).
• Decision Metrics:
  • Net Benefit ($): $\text{Total Monetary Benefits (\$)} - \text{Total Program Costs (\$)} > 0$.
  • Benefit-to-Cost Ratio (BCR): $\frac{\text{Total Monetary Benefits (\$)}}{\text{Total Program Costs (\$)}} > 1.0$.
• Major Limitation: Assigning an objective monetary dollar value to human life, symptom reduction, or averted disability is ethically controversial and methodologically complex (utilizes Willingness-to-Pay surveys or the Human Capital approach based on lost wage earning capacity).

3. Cost-Effectiveness Analysis (CEA)

• Cost Measurement: Monetary units (dollars, $).
• Outcome Measurement: Natural, non-monetary clinical units (e.g., mmHg reduction in systolic blood pressure, mg/dL reduction in LDL cholesterol, percent reduction in HbA1c, life-years gained [LYG], number of asthma exacerbations avoided, cures achieved).
• Advantage: Outcomes reflect real-world clinical endpoints directly monitored by clinicians in ambulatory practice.
• Major Limitation: Can ONLY compare therapeutic options with identical clinical units (cannot compare an antihypertensive program measured in mmHg to an asthma biologic measured in exacerbations).

4. Cost-Utility Analysis (CUA)

• Cost Measurement: Monetary units (dollars, $).
• Outcome Measurement: Quality-Adjusted Life Years (QALYs) or Disability-Adjusted Life Years (DALYs).
• Advantage: Standardizes outcomes by integrating both quantity of life (survival duration) and quality of life (health-related utility/morbidity) into a single composite index. This allows direct economic comparison across entirely different disease states and specialty areas (e.g., comparing oncology immunotherapy vs. cardiovascular secondary prevention vs. rheumatoid arthritis biologics).

2. Utility Measurement & Quality-Adjusted Life Years (QALY)

Health Utility Weights

• A preference-based numerical index ranging from 0.0 (death) to 1.0 (state of perfect health).
• States perceived as worse than death (e.g., severe intractable chronic pain with total disability) can receive negative utility values.

Utility Elicitation Methodologies

1. Standard Gamble (SG): The classic reference method rooted in von Neumann-Morgenstern utility theory. A subject chooses between living in a chronic health state with certainty vs. electing a medical intervention with probability $p$ of achieving perfect health and probability $(1 - p)$ of immediate death. The probability $p$ is varied until the subject is indifferent between the choices; utility equals $p$.
2. Time Trade-Off (TTO): A subject chooses between living $t$ years in a chronic disease state vs. living a shorter duration $x$ in perfect health. Duration $x$ is adjusted until indifference is reached; utility equals $x / t$.
3. Visual Analog Scale (VAS): Rating health states on a 0–100 calibrated thermometer scale (simplest to administer, but lacks economic risk-tradeoff rigor).
4. Standardized Questionnaires: EuroQol 5-Dimension (EQ-5D), Short Form 6-Dimension (SF-6D), and Health Utilities Index (HUI).

Mathematical Calculation of QALYs

A Quality-Adjusted Life Year combines survival duration and health-related quality of life: $\text{QALY} = \\sum \\Big( \text{Time in Health State [Years]} \times \text{Utility Weight} \\Big)$

Clinical Example:

A patient with heart failure lives for 8 years with mild NYHA Class II symptoms (utility = 0.75), after which disease progresses to NYHA Class IV symptoms for 4 years (utility = 0.40): $\text{QALY} = (8 \text{ years} \times 0.75) + (4 \text{ years} \times 0.40) = 6.0 + 1.6 = 7.6 \text{ QALYs}$ Without quality adjustment, the unadjusted survival is 12 life-years; with quality adjustment, the patient experiences 7.6 QALYs.

3. The Incremental Cost-Effectiveness Ratio (ICER) & Decision Plane

When evaluating a new pharmaceutical or clinical service against standard practice, simple average cost-effectiveness ratios are misleading. Pharmacoeconomic evaluation requires an incremental analysis:

The ICER Formula

$\text{ICER} = \frac{\text{Cost}_{\text{New}} - \text{Cost}_{\text{Standard}}}{\text{Effect}_{\text{New}} - \text{Effect}_{\text{Standard}}} = \frac{\\Delta \text{Cost}}{\\Delta \text{Effect}}$

• In Cost-Utility Analysis, $\Delta \text{Effect}$ is measured in QALYs, yielding $\text{ICER} = \Delta C / \Delta \text{QALY}$ (incremental cost per QALY gained).

The Cost-Effectiveness Plane (Four Quadrants)

1. Quadrant I (Northeast): Higher Cost ($+\Delta C$), Higher Effect ($+\Delta E$)
   • The typical scenario for innovative brand-name medications.
   • Decision Rule: Calculate ICER and compare directly against the Willingness-to-Pay (WTP) threshold. If $\text{ICER} \le \text{WTP}$, adopt; if $\text{ICER} > \text{WTP}$, reject or negotiate lower pricing.
2. Quadrant II (Southeast): Lower Cost ($-\Delta C$), Higher Effect ($+\Delta E$)
   • DOMINANT (Win-Win): The new intervention is both more effective and less expensive than standard care.
   • Decision Rule: Automatically adopt without needing an ICER calculation.
3. Quadrant III (Southwest): Lower Cost ($-\Delta C$), Lower Effect ($-\Delta E$)
   • Cheaper, but clinically inferior intervention.
   • Decision Rule: Evaluate whether the cost savings justify the reduction in clinical efficacy.
4. Quadrant IV (Northwest): Higher Cost ($+\Delta C$), Lower Effect ($-\Delta E$)
   • DOMINATED (Lose-Lose): The new intervention is more expensive and less effective than standard care.
   • Decision Rule: Automatically reject.

4. Willingness-to-Pay (WTP) Thresholds & Value Benchmarks

Willingness-to-Pay (WTP) Threshold

The Willingness-to-Pay (WTP) threshold represents the maximum monetary amount a healthcare system, insurer, or society is willing to spend to purchase one additional QALY.

• Historical United States Benchmark: $50,000 per QALY gained (derived in the 1980s based on the estimated annual operating cost of maintaining a patient on chronic hemodialysis funded by Medicare).
• Contemporary United States Benchmarks: $100,000 to $150,000 per QALY gained (adopted by the Institute for Clinical and Economic Review [ICER] in US drug pricing assessments to reflect inflation and modern economic standards).
• United Kingdom (NICE): £20,000 to £30,000 per QALY (with higher thresholds up to £50,000 for end-of-life therapies).
• World Health Organization (WHO) Standard: 1 to 3 times the gross domestic product (GDP) per capita per QALY or DALY gained.

Application to Ambulatory Formulary Decisions

If a newly approved SGLT2 inhibitor costs $4,800/year and provides an additional 0.08 QALYs per patient-year compared to a sulfonylurea ($200/year): $\text{ICER} = \frac{\text{USD } 4{,}800 - \text{USD } 200}{0.08} = \frac{\text{USD } 4{,}600}{0.08} = \text{USD } 57{,}500 \text{ per QALY gained}$ Because $\$57,500 < \$100,000$ (WTP threshold), the SGLT2 inhibitor is deemed highly cost-effective for formulary addition.

5. Perspectives of Pharmacoeconomic Analysis & Cost Taxonomies

Analytical Perspectives

The perspective determines which categories of costs and benefits are included in the economic model:

1. Societal Perspective: The broadest, most comprehensive perspective. Evaluates all costs and health outcomes regardless of who pays or benefits. Includes direct medical costs, direct non-medical costs, and indirect productivity losses (lost wages, caregiver burden). Recommended by the US Panel on Cost-Effectiveness in Health and Medicine for national policy.
2. Third-Party Payer Perspective (Commercial Insurers / Medicare / Medicaid): Focuses exclusively on reimbursed medical costs (prescription drug payments, physician fees, hospitalization reimbursements). Excludes patient copays, transportation, and lost wages.
3. Healthcare Provider / Health System Perspective: Focuses on actual internal operating costs incurred by the clinic or hospital (wholesale acquisition cost of medications, clinical pharmacist salaries, diagnostic testing costs, bed-day costs) rather than billed charges.
4. Patient Perspective: Focuses on out-of-pocket expenses (copayments, coinsurance, deductibles, non-covered OTC drugs), transportation, child care, and lost personal wages.

Cost Taxonomies in Pharmacoeconomics

1. Direct Medical Costs: Direct resources consumed for medical care (e.g., prescription medications, clinical pharmacist consultation fees, physician clinic visits, lab tests, emergency room visits, hospitalizations).
2. Direct Non-Medical Costs: Non-medical resources directly associated with receiving care (e.g., patient transportation/gas to clinic, parking fees, hotel lodging near specialized medical centers, child care during appointments, home renovations like wheelchair ramps).
3. Indirect Costs: Morbidity and mortality costs resulting from illness (e.g., lost productivity, absenteeism [days missed from work], presenteeism [impaired on-the-job productivity], lost future earnings due to premature death).
4. Intangible Costs: Non-monetary physical and emotional consequences of disease (e.g., physical pain, nausea, fatigue, anxiety, depression, grief). Challenging to quantify in dollars; captured within health utility measures (QALYs).

6. Time Preference & Discounting for Future Costs

The Economic Principle of Time Preference

Individuals and societies prefer to receive benefits today rather than in the future and prefer to defer costs to the future rather than pay immediately. Furthermore, capital invested today yields interest over time.

The Discounting Rule

When the time horizon of a pharmacoeconomic evaluation extends beyond one year (12 months), all future costs and future clinical benefits must be discounted back to their Present Value (PV).

The Present Value Formula

$\text{PV} = \frac{\text{FV}}{(1 + r)^t}$ Where:

• $\text{PV} =$ Present Value
• $\text{FV} =$ Future Value (cost or benefit occurring in year $t$)
• $r =$ Annual discount rate (standardized in health economics at 3% to 5% [0.03 to 0.05])
• $t =$ Year in which the cost or benefit occurs

Practical Discounting Calculation:

A pharmacist-led chronic kidney disease clinic avoids a hemodialysis initiation event expected to cost $\$90,000$ in Year 4. Applying a standard annual discount rate of $3\%$ ($r = 0.03$): $\text{PV} = \frac{\text{USD } 90{,}000}{(1 + 0.03)^4} = \frac{\text{USD } 90{,}000}{(1.03)^4} = \frac{\text{USD } 90{,}000}{1.1255} = \text{USD } 79{,}964.46$ The discounted present value of that future cost savings is $\$79,964.46$.